Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride.
about
Does fesoterodine have a role in the treatment of poorly managed patients with overactive bladder?Guidelines for improving the care of the older person with diabetes mellitusUpdate on overactive bladder: pharmacologic approaches on the horizonTolterodine use for symptoms of overactive bladder.Prevalence and predictors of anticholinergic medication use in elderly nursing home residents with dementia: analysis of data from the 2004 National Nursing Home Survey.Temporary cognitive impairment related to administration of newly developed anticholinergic medicines for overactive bladder: two case reportsIntravesical oxybutynin for treating incontinence resulting from an overactive detrusor.The emerging role of solifenacin in the treatment of overactive bladder.Pharmacodynamic effects of darifenacin, a muscarinic M selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers.Muscarinic receptor antagonists for overactive bladder.Pharmacologic treatment for detrusor overactivity.α1-Adrenoceptors and muscarinic receptors in voiding function - binding characteristics of therapeutic agents in relation to the pharmacokinetics.A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.Clinical pharmacology of old age syndromesExploring the affective toxicity of commonly prescribed medications in the elderlyCognitive toxicity of drugs used in the elderly.Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladderDrugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID StudyUrinary Urgency Medications May Compromise Discrete rather than Global Cognitive Skills.Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes.Overactive bladder in the elderly: a guide to pharmacological management.Overactive bladder syndrome in older people.Diagnosis and treatment of dementia: 4. Approach to management of mild to moderate dementia.Nocturia: etiology, diagnosis, and treatment.Neurocognitive costs and benefits of psychotropic medications in older adults.Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin.Social, economic, and health utility considerations in the treatment of overactive bladder.Update on the management of overactive bladder: patient considerations and adherenceTolterodine extended release is well tolerated in older subjectsRationale for the use of anticholinergic agents in overactive bladder with regard to central nervous system and cardiovascular system side effects.Over-Prescribed Medications, Under-Appreciated Risks: A Review of the Cognitive Effects of Anticholinergic Medications in Older Adults.Medicinal chemistry and therapeutic potential of muscarinic M3 antagonists.Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder.Vulnerable elderly patients and overactive bladder syndrome.Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients.Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder.Anticholinergics for overactive bladder therapy: central nervous system effects.Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder.Antimuscarinic treatment in overactive bladder: special considerations in elderly patients.A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs.
P2860
Q27000698-26D1548A-A089-4798-8B6F-577BF9A04568Q28195662-4F225921-D67E-43C8-874F-8390D41803B6Q28203863-032DFD4C-AC12-4CBD-977E-A5C5DA641953Q30799852-61C709F4-152A-4932-A015-D571619C6CEEQ33750631-37CF03E2-3B70-45F9-B1AA-CDA0F74C198EQ34269392-CB3EBA23-B0DF-45D2-B0D0-FC4186CBEAF5Q34285907-38F070E1-40C1-43EF-8FA5-237636E70F66Q34551577-C67EA048-EF54-43D6-ADB6-59DAE73121D0Q34561743-EFAA36CD-2845-4465-97BB-D6D39AB4DC01Q34699525-36246EDB-5A51-4CC1-A34E-BC86B2FF1E01Q34921045-89D74168-02E2-4CFF-A78F-135CD326B7E4Q35183611-5CEA56C6-2847-40E9-B3E3-12E0EEA9E931Q35183619-BE72EA39-FA01-4435-8464-D3ED6E705437Q35200049-0053CA80-8C91-46E8-A0D2-EEAE1B278599Q35236161-B1C3AE7E-A8E4-4C13-95CD-54ECE15B148EQ35236395-60E4650F-D603-4D3E-818B-1770724147FEQ35546189-F604B5B7-EC62-40DC-9963-B6E19CC3A3DAQ35826703-5B99BCF8-C670-464B-BF8A-03DD8C827538Q36100621-02DEE272-783B-4E18-BEA7-A97E3637244BQ36283014-84122639-AE8C-4E64-98D1-96838E402482Q36346373-37E073A6-2B37-4FB2-BEAB-85684C4152A4Q36779724-3F7D62FB-EE48-4659-B917-E3F7DB84CA9FQ36909920-ED78C1EC-A52A-4B80-A311-3FD4CCB61442Q36965934-0768FC5C-6956-4F2B-92AC-B74CCFDDC930Q37001163-DBD69A35-8ABB-4936-942C-656631F7CBDFQ37242704-40ACB97C-3875-40BD-828C-1E9F7CAE91C3Q37283547-8A287D03-F487-4359-B179-9D66A2734F1FQ37283704-2BC75AF7-4EC8-45FE-AEE2-87E35589BDA5Q37332901-A69C182A-5146-4CAA-9A1D-79C064938047Q37399563-A03A403B-EA95-4AFD-A305-866EF23B895BQ37446075-7170BD93-2E3A-4D78-862C-F132E28EEF40Q37462602-905D0BC9-A06F-468F-A883-665711167DADQ37763286-D11AB198-70EE-4DD1-9DCE-9CF34D9897F0Q37784482-C9EE0FE1-ECAA-495B-A87F-584852559FB8Q37879017-B6348E1B-A4DD-43A0-8FA3-7423E92E19BAQ37914849-EB99E343-839F-481F-BE41-516CD851EF2DQ37954372-A1E1370D-8BA3-4EAC-979E-42839378CFE9Q37990531-9C0EC63C-8FF2-4BA3-A06D-7BB475635174Q38020185-29D7B921-B98C-49C9-99BE-07C2038EF05CQ38027567-8E4FD2F0-FBA5-4072-A91F-D50A7EB83E50
P2860
Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Identification of medications ...... e case of oxybutynin chloride.
@en
Identification of medications ...... e case of oxybutynin chloride.
@nl
type
label
Identification of medications ...... e case of oxybutynin chloride.
@en
Identification of medications ...... e case of oxybutynin chloride.
@nl
prefLabel
Identification of medications ...... e case of oxybutynin chloride.
@en
Identification of medications ...... e case of oxybutynin chloride.
@nl
P2093
P2860
P1476
Identification of medications ...... e case of oxybutynin chloride.
@en
P2093
P2860
P356
10.1111/J.1532-5415.1998.TB01006.X
P407
P577
1998-01-01T00:00:00Z